文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急诊科成人急性低氧性呼吸衰竭的高流量鼻导管应用

High flow nasal cannula for adult acute hypoxemic respiratory failure in the ED setting.
PubMed 文献 · Am J Emerg Med · 2021-07-03
一句话结论HFNC在急诊成人急性低氧性呼吸衰竭中可改善氧合、减少部分患者插管需求,但需频繁评估失败风险并及时升级干预。

本文为叙述性综述,评估HFNC在急诊成人急性低氧性呼吸衰竭中的应用。HFNC提供37°C、100%相对湿度的高流量氧气,可改善氧合、降低气道阻力、冲刷解剖死腔并提供低水平PEEP。近期文献显示其在肺炎、ARDS、COVID-19、间质性肺病、免疫抑制状态、围插管期及姑息治疗中有一定疗效,部分情况可减少插管需求、住院时间及死亡率。COVID-19患者使用HFNC需注意感染控制,并频繁评估HFNC失败风险。

要点

  • HFNC提供37°C、100%相对湿度的高流量氧气,可改善氧合、降低气道阻力、冲刷解剖死腔并提供低水平PEEP。
  • 在肺炎、ARDS、COVID-19、间质性肺病、免疫抑制状态、围插管期及姑息治疗中,HFNC在部分情况可减少插管需求、住院时间及死亡率。
  • COVID-19患者使用HFNC需做好感染控制:适当个人防护装备、手卫生、HFNC装置外覆盖外科口罩及环境通风。
  • 使用HFNC患者需频繁重新评估;严重终末器官功能障碍、胸腹不同步、呼吸频率显著增快、HFNC下氧合仍差及心动过速者HFNC失败风险增加,需进一步干预。
  • 急诊环境下HFNC仍需进一步随机试验验证。

适用人群与场景

  • 急诊成人急性低氧性呼吸衰竭患者,包括肺炎、ARDS、COVID-19、间质性肺病、免疫抑制状态、围插管状态及姑息治疗患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • HFNC提供37°C、100%相对湿度的高流量氧气,可提供可靠FiO2,并产生低水平PEEP。
  • COVID-19患者使用HFNC时,需适当个人防护装备、遵守手卫生、在HFNC装置外覆盖外科口罩,并采取环境控制促进充足房间通风。
  • 使用HFNC患者需频繁重新评估;出现严重终末器官功能障碍、胸腹不同步、呼吸频率显著增快、HFNC下氧合仍差及心动过速者,HFNC失败风险增加,需进一步干预。

红旗征与不能漏的情况

  • 严重终末器官功能障碍、胸腹不同步、呼吸频率显著增快、HFNC下氧合仍差及心动过速提示HFNC失败风险增加,需进一步干预。

研究设计与关键结果

  • 本文为叙述性综述,评估成人急性低氧性呼吸衰竭急诊患者使用HFNC的效用;近期文献显示HFNC在肺炎、ARDS、COVID-19、间质性肺病、免疫抑制状态、围插管状态及姑息治疗中有效,部分情况可减少插管需求、住院时间及死亡率。

证据类型、等级与局限

  • 证据类型为叙述性综述;原文指出急诊环境下仍需进一步随机试验。

对床旁实践的改变

  • 急诊成人急性低氧性呼吸衰竭可考虑HFNC支持,但需频繁评估;出现严重终末器官功能障碍、胸腹不同步、呼吸频率显著增快、HFNC下氧合仍差及心动过速时提示失败风险增加,需及时进一步干预。
  • COVID-19患者使用HFNC需落实感染控制措施:适当个人防护装备、手卫生、HFNC装置外覆盖外科口罩及环境通风。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: High flow nasal cannula (HFNC) is a noninvasive ventilation (NIV) system that has demonstrated promise in the emergency department (ED) setting.

OBJECTIVE: This narrative review evaluates the utility of HFNC in adult patients with acute hypoxemic respiratory failure in the ED setting.

DISCUSSION: HFNC provides warm (37 °C), humidified (100% relative humidity) oxygen at high flows with a reliable fraction of inspired oxygen (FiO2). HFNC can improve oxygenation, reduce airway resistance, provide humidified flow that can flush anatomical dead space, and provide a low amount of positive end expiratory pressure. Recent literature has demonstrated efficacy in acute hypoxemic respiratory failure, including pneumonia, acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), interstitial lung disease, immunocompromised states, the peri-intubation state, and palliative care, with reduced need for intubation, length of stay, and mortality in some of these conditions. Individual patient factors play an important role in infection control risks with respect to the use of HFNC in patients with COVID-19. Appropriate personal protective equipment, adherence to hand hygiene, surgical mask placement over the HFNC device, and environmental controls promoting adequate room ventilation are the foundation for protecting healthcare personnel. Frequent reassessment of the patient placed on HFNC is necessary; those with severe end organ dysfunction, thoracoabdominal asynchrony, significantly increased respiratory rate, poor oxygenation despite HFNC, and tachycardia are at increased risk of HFNC failure and need for further intervention.

CONCLUSIONS: HFNC demonstrates promise in several conditions requiring respiratory support. Further randomized trials are needed in the ED setting.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Long B, Liang SY, Lentz S, et al. High flow nasal cannula for adult acute hypoxemic respiratory failure in the ED setting. Am J Emerg Med. 2021. PMID: 34246166. doi:10.1016/j.ajem.2021.06.074

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。